Minerva Surgical, Inc (UTRS) Fair Value & Analysis
Healthcare · US · Market cap $887
Minerva Surgical, Inc
UTRS · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $8.71 to $0.0001 (−100.0%) since Jun 25, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0010 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Minerva Surgical, Inc (UTRS) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Minerva Surgical, Inc generated revenue of $51.7M at a net margin of -64.7%. Revenue declined 4.9% year over year. Net debt stands at $32.7M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps; and HERizon electronic disposable hysteroscope, image processor, Hysto-Kit, and endoscopic accessories that helps gynecologists to evaluate abnormal uterine bleeding and provide care. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Minerva Surgical, Inc reported revenue of $51.7M in FY2023 versus $26.0M in FY2019, a compound +18.7%/yr. Reported net income was −$33.5M in FY2023.
Is UTRS fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$39.41 | R$30.42 | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €35.10 | €26.55 | -24% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Minerva Surgical, Inc (UTRS) undervalued?
What is the fair value of UTRS?
What is the quality score of UTRS?
What is the revenue of Minerva Surgical, Inc (UTRS)?
What is the net profit margin of UTRS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.